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Immunosuppressive agents are generally administered to treat kidney diseases.  However,  it is unclear 
whether renal stem/progenitor cells are directly aﬀected by the immunosuppressive agents.  We used 
normal rat kidney cells,  ureteric bud cells and rat kidney stem/progenitor cells in this study.  
Mizoribine (MZR),  cyclophosphamide (CPA) and cyclosporine (CyA) were added to the culture media 
of these cells.  We evaluated the eﬀects of these immunosuppressive agents on cell proliferation using 
an electrical cell-substrate impedance sensing system (ECIS) and their eﬀects on the process of renal 
regeneration using the ischemia-reperfusion (I/R) injury rat model.  The ECIS data showed that prolif-
eration of each of the 3 types of cells was signiﬁcantly suppressed by MZR.  MZR treatment enhanced 
renal tubular injury in ischemia-reperfusion (I/R) injured rats,  and signiﬁcantly decreased levels of 
M-phase cells and Nestin-positive cells.  These results suggested that MZR inhibits the cell cycle of renal 
stem/progenitor cells; thus,  physicians should take note that MZR might aﬀect not only inﬂammation 
but also renal regeneration.
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he incidence of chronic kidney disease (CKD) 
has increased over the last several decades 
worldwide,  and CKD is recognized as a risk factor of 
cardiovascular disease.  CDK can progress to end-
stage kidney disease (ESKD),  which has no cure and 
therefore requires renal replacement therapy,  namely,  
dialysis or renal transplantation.  The costs of treating 
ESKD have been reported to be greater than the 
direct treatment costs of cancer [1].  Regenerative 
medicine using stem cells is one of the clinical goals 
for treating kidney disease.
　 Regarding stem cells in renal tissue,  several stud-
ies have focused on the regeneration that occurs sub-
sequent to acute tubular injury.  Morphological analy-
sis of renal repair after acute tubular injury has long 
suggested that new tubular cells are generated by the 
proliferation of pre-existing tubular cells [2-4].  In 
addition,  Sagrinati et al.  reported that CD24＋
CD133＋ parietal epithelial cells in Bowmanʼs cap-
sules obtained from humans have self-renewal potential 
and a high cloning eﬃciency [5].  In addition,  
Kitamura et al.  reported having established renal 
progenitor-like cells,  named rKS56 cells,  from the S3 
segment of nephrons in the adult rat kidney.  These 
cells exhibit the properties of self-renewal,  multi-
plasticity and the ability to repair tissue [6].  It is 
expected that kidney regenerative therapy could use 
such cells.
　 Chronic glomerulonephritis is the underlying dis-
ease in many cases of ESKD,  and immunosuppressive 
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drugs are generally used to treat it.  Immunosuppressive 
drugs act mainly on lymphocytes.  These drugs sup-
press T-cell or B-cell proliferation by aﬀecting DNA 
synthesis,  control nephritis through their anti-inﬂam-
matory eﬀects,  and prevent nephropathic progression.  
However,  it is unclear whether renal constitutive cells 
are directly aﬀected by the immunosuppressants.  
Recently,  the eﬀects of cyclosporin (CyA) on podocyte 
proliferation [7] and mizoribine (MZR) on mesangial 
cell proliferation [8] have been reported,  however the 
inﬂuence for renal regeneration by immunosuppressive 
drugs is not known clearly.
　 We investigated how the immunosuppressive drugs 
typically administered for nephritis treatment aﬀect 
kidney constitutive cells and renal regeneration.  We 
examined the eﬀects of cyclosporin,  cyclophosphamide 
and mizoribine on 3 types of diﬀerentiated renal cells.  
In addition,  we evaluated whether the immunosup-
pressive drugs aﬀect the regeneration process subse-
quent to renal damage using a kidney ischemia-reper-
fusion injury rat model.
Materials and Methods
　 Cell culture and phase-contrast microscopy.
We used NRK52E cells,  UB (ureteric bud) cells,  and 
rKS56 cells.  The NRK-52E cells were purchased 
from Riken (Wako,  Saitama,  Japan).  UB tissues were 
dissected with ﬁne forceps from the kidneys of 
embryos obtained from timed-pregnant SD rats (Crea 
JAPAN) on embryonic day 13 (e13).  The UB cells 
were cultured on type-IV collagen (BD Biosciences,  
San Jose,  CA,  USA) and maintained in K＋J medium 
(a 1 : 1 mixture of the culture supernatant (DMEM 
containing 10ｵ FCS) of mouse mesenchymal cells 
(MCS) and modiﬁed K1 medium (1 : 1 mixture of 
DMEM and Hamʼs F12 medium,  supplemented with 
10ｵ FCS,  5µg/ml insulin,  2.75µg/ml transferrin,  
3.35ng/ml sodium selenious acid (GIBCO,  Langley,  
OK,  USA),  50nM hydrocortisone (Sigma,  Ronkonkoma,  
NY,  USA),  25ng/ml of hepatocyte growth factor 
(Sigma) and 2.5mM nicotinamide (Sigma) at 37℃ with 
5ｵ CO2 and 100ｵ humidity.  Cell outgrowth was 
observed after 7 days.  We harvested the cells and 
used the limiting dilution method to obtain single cells.  
Finally,  we harvested a monoclonal UB cell line.  We 
used the cells from passages 4-8 for this study.  The 
rKS56 cells were obtained as described previously 
[6].  We used rKS56 cells from passages 8-10.  To 
evaluate the eﬀect of immunosuppressive agents on 
NRK,  UB,  and rKS56 cells,  they were seeded in 
96-well plates coated with type-IV collagen at a con-
centration of 1×104 cells/well.  The cells were cul-
tured in K＋J medium and treated with PBS,  DMSO 
(Sigma),  MZR (Sigma) dissolved in PBS (ﬁnal con-
centrations: 0.1,  1,  and 10µg/ml),  cyclophosphamide 
(CPA,  Sigma) dissolved in PBS (ﬁnal concentrations:  
1,  10,  and 100µM),  or CyA (Sigma) dissolved in 
DMSO (ﬁnal concentrations: 10,  100,  and 1,000ng/
ml).  We chose the concentrations of these drugs based 
on published reports [9-11].  After 7 days of incuba-
tion,  we observed the cells by phase-contrast micros-
copy using an FSX100 (Olympus) instrument.
　 Electrical cell-substrate impedance sensing 
system (ECIS). In this study,  we used 8-cham-
bered electrode wells (8W10E＋ slide).  Prior to 
seeding the cells,  the electrode wells were immersed 
in an aqueous solution of 10mM L-cysteine (Sigma).  
After being washed twice with PBS,  they were coated 
with mouse type-IV collagen (BD Biosciences) at a 
concentration of 10µg/cm2.  NRK,  UB,  and rKS56 
cells were inoculated at a concentration of 1×104 
cells/well in K＋J medium.  We divided the cells into 
4 groups,  the positive control group (PC: treated 
with PBS,  n＝4),  a group treated with 0.1µg/ml of 
MZR (MZR0.1,  n＝4),  a group treated with 1µg/ml 
of MZR (MZR1,  n＝4),  and a group treated with 
10µg/ml of MZR (MZR10,  n＝4).  The well station 
was placed in the incubator,  and the well plates were 
placed in it.  The well plates were maintained in an 
ordinary humidiﬁed cell culture incubator at 37℃ 
with 5ｵ CO2 (v/v).  We measured resistance and 
capacitance for 180h.  The ECIS system was obtained 
from (Applied BioPhysics,  Inc,  NY,  USA).
　 Eﬀect of immunosuppressive agents for tubu-
lar regeneration in ischemia-reperfusion model 
rat. The experimental protocol was approved by 
the Animal Ethics Review Committee of the Okayama 
University Graduate School of Medicine,  Density and 
Pharmaceutical Sciences.  Male SD rats (Crea 
JAPAN Inc.,  Tokyo,  Japan) weighing 100-150g were 
maintained under conventional laboratory conditions 
and given free access to water and food.  They were 
divided into 5 groups of 3 rats each.  In sham-operated 
group,  a midline abdominal incision was made under 
sodium pentobarbital-induced anesthesia.  In the posi-
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tive control group (PC),  acute renal failure (ARF) 
was induced by clamping the left renal artery for 
40min after removing the right kidney (ischemia-
reperfusion: I/R).  In the MZR group,  ARF was 
induced with 3mg/kg of MZR that was infused into the 
peritoneal cavity for 6 days post-surgery.  In the CPA 
group,  ARF was induced with 3mg/kg of CPA that 
was infused into the peritoneal cavity for 6 days post-
surgery.  In the CyA group,  ARF was induced with 
3mg/kg of CyA that was infused into the peritoneal 
cavity for 6 days post-surgery.  At 7 days post-sur-
gery,  the rats were sacriﬁced.  The left kidneys were 
removed and processed by formalin ﬁxation followed 
by paraﬃn-embedding or frozen-sectioning.  Blood 
samples were drawn from the vena cava inferior under 
anesthesia.  We measured creatinine (Cre),  and blood 
urea (BUN) as renal injury markers.  We made 
4-µm-thick sections from the kidney samples.  We 
stained the sections with anti-phospho Histone H3 
antibody (Millipore) and anti-Nestin antibody (Santa 
Cruz) for the 1st antibody and Alexa antibody for the 
2nd antibody (Invitrogen).  These tissues were exam-
ined by confocal microscopy using an FSX100 
(Olympus) instrument with a 20× objective.  The 
numbers of phosphor Histone H3-positive and Nestin-
positive cells in 1 ﬁeld of view were counted,  and the 
mean numbers of positive cells from 5 ﬁelds of view 
for each group were used for comparison.
　 Statistical analysis. The ECIS data were 
analyzed by the Wilcoxon test using the JMP for 
Windows software package version 8.0.2 (SAS 
Institute Inc.,  Cary,  NC,  USA).  The data for the 
BrdU-positive cell counts were analyzed by an 
ANOVA test using SPSS version 19.0J software for 
Windows (IBM Corporation,  Somers,  NY,  USA).  P 
values ＜0.05 were considered to be statistically sig-
niﬁcant.
Results
　 MZR suppressed the proliferation of the three 
types of renal cells. Phase-contrast image micros-
copy showed that the proliferation of NRK cells was 
suppressed by MZR at a concentration of 1 or 10µg/
ml (Fig.  1A).  The proliferation of UB and rKS56 
cells was also suppressed by MZR at 1µg or 10µg/
ml (Fig.  1B and 1C).  However,  CPA and CyA did 
not aﬀect the proliferation of the 3 types of cells.  We 
had hypothesized that immunosuppressive agents 
would aﬀect the diﬀerentiation of renal cells,  but we 
did not observe morphological changes in the cells 
treated with any of the immunosuppressive agents.
　 Cell proliferation was suppressed by MZR in 
a dose-dependent manner. Using ECIS,  we could 
quantitatively evaluate cell proliferation.  A decrease 
in the capacitance indicates cell proliferation and an 
increase in the resistance reﬂects cell proliferation.  
The ECIS data (Fig.  2) showed that the capacitance 
of the 3 cell types was signiﬁcantly higher in the 
groups treated with 1 or 10µg/ml doses of MZR 
compared with the group treated with 0.1µg/ml of 
MZR and the positive control group (p＜0.05).  For 
the NRK cells,  the group treated with 10µg/ml of 
MZR exhibited higher capacitance compared with the 
group treated with 1µg/ml of MZR (p＜0.05).  
However,  the ECIS data for the UB and rKS56 cells 
treated with 10µg/ml of MZR were not signiﬁcantly 
diﬀerent from the corresponding data for the groups 
of each cell type treated with 1µg/ml of MZR.  These 
results suggested that MZR suppressed cell prolifera-
tion and that the proliferation-suppressive capacity of 
MZR is dose-dependent.
　 MZR may inhibit renal regeneration after 
ischemia-reperfusion tubular injury. To deter-
mine whether MZR aﬀects renal regeneration follow-
ing tubular injury due to cell cycle arrest,  we evalu-
ated tubular damage and the content of M-phase renal 
cells in the renal ischemia-reperfusion rat model.  Two 
weeks after ischemia-reperfusion injury,  tubular dam-
age was not observed in the positive control group 
(Fig.  3B).  Moreover,  tubular damage was not observed 
in the CPA- (Fig.  3D) and CyA- (Fig.  3E) treated 
groups.  However,  vacuolar degeneration of tubular 
epithelial cells was observed in the MZR-treated 
group (arrows in Fig.  3C).  In the groups treated with 
MZR,  CPA and CyA,  the Cre and BUN levels were 
slightly higher than those of the sham-operated group 
However,  we could not observe any signiﬁcant diﬀer-
ences among the I/R-,  MZR-,  CPA- and CyA-treated 
groups (Fig.  3F and G).  Additionally,  we stained 
with Phospho Histone H3 to detect M-phase cells 
(Fig.  4 A-E,  and F).  In the groups treated with 
immunosuppressive agents without MZR,  the numbers 
of M-phase cells were drastically increased compared 
with those of the sham-operated and PC groups.  
Regarding the immunosuppressive agents,  the number 
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Fig. 1　 A,  Eﬀects of immunosuppressive agents on NRK cells.  Phase-contrast microscopy showed that the proliferation of NRK cells 
was suppressed by MZR at concentrations of 1 (c) or 10 (d) µg/ml.  Although we used diﬀerent doses of CPA and CyA,  no treatment with 
CPA or CyA suppressed the proliferation of NRK cells.  We observed no change in the morphology of NRK cells treated with any of the 
immunosuppressive agents; B,  Eﬀects of immunosuppressive agents on UB cells.  Phase-contrast microscopy showed that the proliferation 
of UB cells was also suppressed by MZR at 10µg/ml (Fig.  Bd).  Treatment with CPA or CyA did not suppress the proliferation of UB cells.  
UB cell morphology was not changed by treatment with any of the immunosuppressive agents; C,  Eﬀects of immunosuppressive agents on 
rKS56 cells.  Phase-contrast microscopy showed that the proliferation of the rKS56 cells was suppressed by MZR at concentrations of 
1µg/ml (c) or 10µg/ml (d).  However,  treatment with CPA or CyA did not suppress the proliferation of rKS56 cells.  rKS56 cell morphology 
was not changed by treatment with any of the immunosuppressive agents.  Scale bar: 100µm.  a,  negative control; b,  0.1µg/ml of 
MZR; c,  1µg/ml of MZR; d,  10µg/ml of MZR; e,  PBS; f,  1µm of CPA; g,  10µm of CPA; h,  100µm of CPA; i,  DMSO; j,  10ng/ml 
of CyA; k,  100ng/ml of CyA; l,  1,000ng/ml of CyA.  MZR,  mizoribine; CPA,  cyclophosphamide; CyA,  cyclosporin.
11Mizoribine Regulates Renal Cell GrowthFebruary 2014
・― ・―
・― ・―
A B
D
C
E F
＊
＊
PC MZR 0.1μg/ml
MZR 1μg/ml MZR 10μg/ml
N
or
m
. R
es
is
ta
nc
e
N
or
m
. R
es
is
ta
nc
e
N
or
m
. R
es
is
ta
nc
e
N
or
m
. C
ap
ac
ita
nc
e
N
or
m
. C
ap
ac
ita
nc
e
N
or
m
. C
ap
ac
ita
nc
e
Time (h) Time (h)
Time (h)Time (h)
Time (h) Time (h)
＊
＊
＊
＊
＊
＊
＊
＊
＊
＊
Fig. 2　 Cell proliferation analysis using the electrical cell-substrate impedance sensing system (ECIS).  The cells were divided into 4 
groups,  the positive control group (PC),  a group treated with 0.1µg/ml of MZR (MZR0.1,  n＝4),  a group treated with 1µg/ml of MZR 
(MZR1,  n＝4),  and a group treated with 10µg/ml of MZR (MZR10,  n＝4).  (A) The ECIS data showed that the capacitance of the NRK 
cells was signiﬁcantly higher in the MZR1 and MZR10 groups compared with PC and MZR0.1 groups (PC vs.  MZR1,  PC vs.  MZR10,  
MZR0.1 vs.  MZR1,  MZR0.1 vs.  MZR10,  MZR1 vs.  MZR10,  p＜0.05).  (B) The resistance of the NRK cells in the MZR1 and MZR10 
groups was signiﬁcantly decreased compared to those of the other NRK groups (PC vs.  MZR1,  PC vs.  MZR10,  MZR0.1 vs.  MZR1,  
MZR0.1 vs.  MZR10,  MZR1 vs.  MZR10,  p＜0.05).  As was found for the NRK cells,  the capacitance (C) and resistance (D) of the UB 
cells in the MZR1 and MZR10 groups were signiﬁcantly diﬀerent from those of the PC and MZR0.1 groups (PC vs.  MZR1,  PC vs.  MZR10,  
MZR0.1 vs.  MZR1,  MZR0.1 vs.  MZR10,  p＜0.05).  The capacitance (E) and resistance (F) of the rKS56 cells exhibited the same pattern 
of diﬀerences (PC vs.  MZR1,  PC vs.  MZR10,  MZR0.1 vs.  MZR1,  MZR0.1 vs.  MZR10,  p＜0.05). 　＊p＜0.05.
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Fig. 3　 Eﬀect of immunosuppressive agents on the I/R rat kidney model.  Two weeks after I/R injury,  tubular damage was not observed 
in the positive control group,  the CPA-treated group,  or the CyA-treated group.  However,  in the MZR-treated group,  vacuolar degenera-
tion of tubular epithelial cell was observed (arrows in c).  A,  sham-operated group; B,  positive control group; C,  MZR-treated group; D,  
CPA-treated group; E,  CyA-treated group.  Three independent animals from each group showed similar ﬁndings.  Scale bar: 200µm; F,  
The Cre levels were slightly higher in the ARF groups with/without immunosuppressive agents than in the sham-operated group (each 
group: n＝3); G,  The BUN levels were slightly higher in the ARF groups with/without immunosuppressive agents than in the sham-oper-
ated group (each group: n＝3).
of M-phase cells in the renal cortex was lower in the 
MZR-treated group compared with the CPA- and 
CyA-treated groups (＊p＜0.05,  ＊＊p＜0.01 for both 
comparisons).  In addition,  Nestin,  which is reported 
as an immature cell marker,  was signiﬁcantly decreased 
in the MZR-treated group (Fig.  4A-E,  and G).  These 
results suggested that MZR inhibits cell division and 
immature cell proliferation.  The inhibition of cell 
proliferation may be lead to inhibit the recovery for 
renal regeneration.
Discussion
　 Immunosuppressive agents have been reported to 
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Fig. 4　 Phospho Histone H3 positive and Nestin-positive cells in the I/R rat kidney.  Scale bar: 50µm.  A-E) Phospho Histone H3,  
green; Nestine,  red; DAPI,  blue.  A,  sham-operated group; B,  I/R injury positive control group; C,  the group with I/R injury treated with 
3mg/kg of MZR; D,  the group with I/R injury treated with 3mg/kg of CPA; E,  the group with I/R injury treated with 3mg/kg of CyA.  
Three independent animals from each group showed similar ﬁndings; F,  Phospho Histone H3-positive cells decreased signiﬁcantly in MZR-
treated group compared to the CPA- and CyA-treated groups; G,  The Nestine-positive area decreased signiﬁcantly in the MZR-treated 
group compared to the CPA- and CyA-treated groups.  Each group contained 3 animals.  Each animal was evaluated in 5 ﬁelds in the sec-
tions.  (＊p＜0.05,  ＊＊p＜0. 01)
cause renal injury.  The major limiting factors for the 
use of CyA are its acute and long-term toxic eﬀects on 
the kidney.  In the short term,  CyA induces a revers-
ible reduction in renal blood ﬂow and the glomerular 
ﬁltration rate [12].  In the long term,  CyA treatment 
leads to irreversible renal failure characterized by 
extensive tubulointerstitial ﬁbrosis [13].  It was 
recently reported that Nox2,  the classic NADPH 
oxidase of phagocytes,  plays an important role in 
calcineurin inhibitor-induced renal ﬁbrosis [14].  In 
addition,  tubular cell injury and ﬁbrosis are key fea-
tures of calcineurin inhibitor nephrotoxity [15].  
Oxidative stress may play a role in CPA-induced renal 
damage.  Intraperitoneal administration of CPA has 
been reported to increase the level of malondialde-
hyde,  decrease the level of glutathione,  and decrease 
the activities of antioxidative enzymes in the kidney,  
including superoxide dismutase,  glutathione peroxi-
dase,  glutathione reductase,  and catalase [16-19].  
MZR may induce acute renal failure due to the hype-
ruricemia associated with mizoribine therapy [20].  
However,  the exact mechanisms of immunosuppres-
sive agent-induced renal damage remain to be fully 
elucidated.  There are various reports about the 
amount of renal damage caused by immunosuppressive 
agents,  but how these drugs aﬀect the regeneration 
process following renal damage is not known.  In our 
study,  MZR was shown to inhibit the proliferation of 
renal constitutive cells (Fig.  1,  2).  This eﬀect may 
depend on the drug dosage.  Therefore,  we investi-
gated the eﬀect of immunosuppressive agents on the 
cell cycle.  Our ﬂow cytometry analysis demonstrated 
that the proportion of G1/S phase cells was increased 
by MZR treatment (data not shown).  Liu S et al.  
reported that MZR down-regulated the expression of 
Skp2,  a member of the SCFSkp2 ubiquitin ligase com-
plex that is responsible for p27kip1 degradation,  and 
induced G1/S arrest in mesangial cells.  In addition,  
they found that MZR induced G1/S arrest by inhibit-
ing de novo purine synthesis.  In their report,  because 
a DNA synthesis inhibitor did not increase the level of 
p27kip1 protein as MZR did,  they concluded that the 
eﬀect of MZR on the p27kip2 protein level was not 
dependent on inhibiting DNA synthesis [8].  We did 
not examine these mechanisms of MZR.  The eﬀect of 
MZR on the renal cell cycle may not be due to inhibit-
ing purine metabolism.
　 Injury models with proximal tubule damage,  such 
as I/R or nephrotoxin models,  have been extensively 
used to study tubular regeneration.  Kidney regenera-
tion after I/R injury requires approximately 1 week.  
It was reported that proliferating tubular epithelial 
cells are not observed before I/R injury,  but they are 
observed after I/R injury [21].  As previously described,  
MZR may block the renal cell cycle in the G1/S 
phase,  and decrease the number of M-phase cells.  In 
addition,  the immature cells in the adult rat kidney 
were inhibited from proliferating in the MZR-treated 
group.  This suggested that MZR would prolong the 
regeneration of renal tubule cells after I/R injury.  
H&E-staining conﬁrmed that the recovery of MZR-
treated rats from tubular injury was prolonged.
　 The rKS56 cells that we used in this study origi-
nated in the S3 segment of nephrons,  and have the 
properties of self-renewal,  multi-plasticity and the 
ability to repair tissue [6].  Therefore,  cells similar 
to rKS56 cells may be involved in tubular regenera-
tion.  Our in vitro study demonstrated that MZR sup-
pressed the proliferation of rKS56 cells,  and in our 
animal study,  M-phase cells in I/R and Nestin-positive 
cells decreased signiﬁcantly with treatment by MZR 
compared with other immunosuppressive agents.  MZR 
may have a more potent eﬀect on the proliferation of 
cells that are involved in tubular regeneration than do 
the other immunosuppressive agents.  Neither CPA 
nor CyA suppressed proliferation of rKS56 or UB 
cells in vitro,  and we observed no tubular damage from 
treatment with these drugs in vivo.  However,  the 
mechanisms and the cells involved in the regeneration 
of renal tubules have not yet been elucidated.
　 In conclusion,  we evaluated the eﬀect of immuno-
suppressive agents on renal constitutive cells.  CyA 
and MZR arrested the cell cycle of renal cells.  
Additionally,  MZR may inhibit renal tubular regen-
eration by blocking the cell cycle of renal stem/pro-
genitor cells.
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